transmedТрансляционная медицинаTranslational Medicine2311-44952410-5155Almazov National Medical Research Centre, Saint Petersburg, Russia10.18705/2311-4495-2015-0-6-64-69transmed-107Research ArticleЭКСПЕРИМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯEXPERIMENTAL STUDIESРоль мочевой кислоты в развитии когнитивных расстройств у пациентов с метаболическим синдромомThe role of uric acid in the development of cognitive disorders in patients with metabolic syndromeЗуеваИ. Б.ZuevaI. B.iravit@yandex.ruГоликоваР. В.GolikovaR. V.noemail@neicon.ruКривоносовД. С.KrivonosovD. S.noemail@neicon.ruУрумоваЕ. Л.UrumovaE. L.noemail@neicon.ruБараташвилиГ. Г.BaratashviliG. G.noemail@neicon.ruФГБУ «Северо-Западный федеральный медицинский исследовательский центр имени В.А. Алмазова»РоссияFederal Almazov North-West medical research centre named after V. A. AlmazovRussian FederationГБОУ ВПО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова»РоссияFirst St. Petersburg Pavlov State Medical UniversityRussian Federation201523122016066469Copyright © Зуева И.Б., Голикова Р.В., Кривоносов Д.С., Урумова Е.Л., Бараташвили Г.Г., 20162016Зуева И.Б., Голикова Р.В., Кривоносов Д.С., Урумова Е.Л., Бараташвили Г.Г.Zueva I.B., Golikova R.V., Krivonosov D.S., Urumova E.L., Baratashvili G.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://transmed.almazovcentre.ru/jour/article/view/107

Цель исследования. Оценить роль увеличения уровня мочевой кислоты в развитии когнитивных расстройств у пациентов с метаболическим синдромом (МС). Материалы и методы. В исследование были включены и обследованы с использованием антропометрии, биохимического анализа крови 84 пациента с МС (n = 44 с когнитивными нарушениями и n = 40 без когнитивного дефицита). Когнитивные функции оценивались с помощью применения нейропсихо-логических шкал. Количественная оценка когнитивных функций определялась методом когнитивного вызванного потенциала с помощью ЭМГ/ ВП Nicolet Viking Select. Результаты. Было выявлено увеличение уровня мочевой кислоты (0,54 ± 0,32 и 0,36 ± 0,15 ммоль/л, соответственно, р < 0,01) в группе пациентов с МС и когнитивными нарушениями по сравнению с группой без когнитивных расстройств. Отмечалась тесная корреляционная связь между уровнем мочевой кислоты и параметрами нейродинамического тестирования. У пациентов с повышением уровня мочевой кислоты было зарегистрировано увеличение продолжительности латентного периода когнитивного вызванного потенциала (г = 0,42, p = 0,002). Выводы. Полученные результаты дают основание предполагать, что одним из механизмов развития когнитивных нарушений у пациентов с МС является увеличение уровня мочевой кислоты в сыворотке крови.

Objective. To evaluate the role of increased level of uric acid in the development of cognitive disorders in patients with metabolic syndrome (MS). Design and methods. Were included in the study and examined using anthropometry, biochemical blood analysis of 84 patients with MS (n = 44 with cognitive impairments and n = 40 without cognitive deficits). Cognitive function was assessed by applying neuropsychological scales. Quantitative assessment of cognitive functions was determined by the method of cognitive evoked potential with EMG/EP Nicolet Viking Select. Results. Revealed increased levels of uric acid (0,54 ± 0,32 and 0,36 ± 0,15 mmol/l, respectively, p < 0.01) in the group of patients with MS and cognitive disorders compared with the group without cognitive disorders. There was correlation between the level of uric acid and parameters of neurodynamic testing. In patients with increased uric acid level was registered the increase of the duration of the latent period of cognitive evoked potential (r = 0,42, p = 0,002). Conclusion. The obtained results give reason to assume that one of the mechanisms of development of cognitive impairment in patients with MS is to increase the level of uric acid in serum.

мочевая кислотакогнитивный дефицитметаболический синдромuric acidcognitive dysfunctionmetabolic syndromeReferencesBos M.J. Uric acid is a risk factor for myocardial infarction and stroke; The Rotterdam Study. Stroke. 2006; 37: 1503.Bos M.J. Uric acid is a risk factor for myocardial infarction and stroke; The Rotterdam Study. Stroke. 2006; 37: 1503.Zhu X., Raina A.K., Perry G. et al. Alzheimer>s disease: the two-hit hypothesis. Lancet Neurol. 2004;3: 219-26.Zhu X., Raina A.K., Perry G. et al. Alzheimer>s disease: the two-hit hypothesis. Lancet Neurol. 2004;3: 219-26.Johnson R. J., Kang D. H., Feig D. et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003; 41: 1183-90.Johnson R. J., Kang D. H., Feig D. et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003; 41: 1183-90.Kim T.S., Pae C.U., Yoon S.J. et al. Decreased plasma antioxidants in patients with Alzheimer>s disease. Int J Geriatr Psychiatry. 2006; 21: 344-8.Kim T.S., Pae C.U., Yoon S.J. et al. Decreased plasma antioxidants in patients with Alzheimer>s disease. Int J Geriatr Psychiatry. 2006; 21: 344-8.Schretlen D.J., Inscore A.B., Vannorsdall T.D. et al. Serum uric acid and brain ischemia in normal elderly adults. Neurology. 2007; 69: 1418-1423.Schretlen D.J., Inscore A.B., Vannorsdall T.D. et al. Serum uric acid and brain ischemia in normal elderly adults. Neurology. 2007; 69: 1418-1423.Irizarry M.C., Reman R., Schwarzschild M.A. et al. Plasma urate and progression of mild cognitive impairment. Neurodegener Dis.- Dec 2009; 6(1-2): 23-28.Irizarry M.C., Reman R., Schwarzschild M.A. et al. Plasma urate and progression of mild cognitive impairment. Neurodegener Dis.- Dec 2009; 6(1-2): 23-28.Vernoolj M.W., Ikram M.A., Vrooman H.A. et al. White matter microstructural integrity and cognitive function in a general elderly population. Arch Gen Psychiatry. 2009 May; 66 (5): 545-53.Vernoolj M.W., Ikram M.A., Vrooman H.A. et al. White matter microstructural integrity and cognitive function in a general elderly population. Arch Gen Psychiatry. 2009 May; 66 (5): 545-53.Ford E.S., Li C., Cook S., Choi H.K. Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation. 2007; 115 (19): 2526-2532.Ford E.S., Li C., Cook S., Choi H.K. Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation. 2007; 115 (19): 2526-2532.Pacifico L., Cantisani V., Anania C., et al. Serum uric acid and its association with metabolic syndrome and carotid atherosclerosis in obese children. European Journal of Endocrinology. 2009; 160 (1): 45-52.Pacifico L., Cantisani V., Anania C., et al. Serum uric acid and its association with metabolic syndrome and carotid atherosclerosis in obese children. European Journal of Endocrinology. 2009; 160 (1): 45-52.Kramer C.K., von Mühlen D., Jassal S.K., Barrett-Connor E. Serum uric acid levels improve prediction of incident type 2 diabetes in individuals with impaired fasting glucose: the Rancho Bernardo Study. Diabetes Care. 2009; 32 (7): 1272-1273.Kramer C.K., von Mühlen D., Jassal S.K., Barrett-Connor E. Serum uric acid levels improve prediction of incident type 2 diabetes in individuals with impaired fasting glucose: the Rancho Bernardo Study. Diabetes Care. 2009; 32 (7): 1272-1273.Lee Y.J., Lee J.H., Shin Y.H. et al. Gender difference and determinants of C-reactive protein level in Korean adults. Clinical Chemistry and Laboratory Medicine.- 2009; 47 (7): 863-869.Lee Y.J., Lee J.H., Shin Y.H. et al. Gender difference and determinants of C-reactive protein level in Korean adults. Clinical Chemistry and Laboratory Medicine.- 2009; 47 (7): 863-869.Kang D-H., Park S-K., Lee I-K., Johnson R.J. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. Journal of the American Society of Nephrology. 2005;16 (12): 3553-3562.Kang D-H., Park S-K., Lee I-K., Johnson R.J. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. Journal of the American Society of Nephrology. 2005;16 (12): 3553-3562.Sowers J.R., Whaley-Connell A., Hayden M.R. The role of overweight and obesity in the cardiorenal syndrome. Cardiorenal Med. 2011; 1: 5-12.Sowers J.R., Whaley-Connell A., Hayden M.R. The role of overweight and obesity in the cardiorenal syndrome. Cardiorenal Med. 2011; 1: 5-12.Sowers J.R. Diabetes mellitus and vascular disease. Hypertension. 2013; 61: 943-947.Sowers J.R. Diabetes mellitus and vascular disease. Hypertension. 2013; 61: 943-947.Fazekas F., Schmidt R., Scheltens P. Pathophysiologic mechanisms in the development of age-related white matter changes of the brain. Dement Geriatr Cogn Disord.- 1998; 9 (suppl 1): 2-5.Fazekas F., Schmidt R., Scheltens P. Pathophysiologic mechanisms in the development of age-related white matter changes of the brain. Dement Geriatr Cogn Disord.- 1998; 9 (suppl 1): 2-5.

The authors declare that there are no conflicts of interest present.